drugset / Trial / NCT01001104
A Study of LY2189265 in Japanese Patients With Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.
Timeline
- Start
- 2009-10
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulaglutide | Peptide | 0.25 mg | Subcutaneous |
| Subject | Dulaglutide | Peptide | 0.5 mg | Subcutaneous |
| Subject | Dulaglutide | Peptide | 0.75 mg | Subcutaneous |